电针联合艾灸治疗重性抑郁障碍患者:随机对照试验研究方案
本研究为一项双组平行、患者与评估者盲法、多中心、随机假对照试验性临床研究方案,拟纳入30例19至65岁重性抑郁障碍(MDD)患者,按1:1随机分配接受真或假电针/艾灸治疗,共8周20次,主要结局为汉密尔顿抑郁量表,旨在评估开展全规模随机对照试验的可行性。
要点
- 研究为多中心、随机、假对照试验性临床试验,拟纳入30例MDD患者。
- 治疗组接受真电针/艾灸,对照组接受假电针/艾灸,共8周20次。
- 主要结局为汉密尔顿抑郁量表,并评估失眠、焦虑、生活质量及脑电图等。
核心结论
- 该试验结果将为后续评估电针联合艾灸治疗MDD疗效与安全性的研究提供依据。
研究设计与样本
- 研究为双组平行、患者与评估者盲法、多中心、随机假对照试验性临床试验。
主要发现
- 研究将纳入30例19至65岁MDD患者,按1:1随机分配至治疗组和对照组。
- 治疗组和对照组分别接受真和假电针/艾灸治疗,共8周20次。
- 主要结局为汉密尔顿抑郁量表,次要结局包括贝克抑郁量表、失眠严重指数、状态-特质焦虑量表、欧洲五维健康指数量表、Measure Yourself Medical Outcome Profile version 2及脑电图。
- 每次访视监测不良事件以评估安全性,所有结局由对治疗分配设盲的研究者评估和分析。
- 数据将在治疗前后及4周随访期间进行分析。
关键数值与推荐
- 主要结局为汉密尔顿抑郁量表评分。
- 次要结局包括贝克抑郁量表、失眠严重指数、状态-特质焦虑量表、欧洲五维健康指数量表、Measure Yourself Medical Outcome Profile version 2和脑电图。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder (MDD) is one of the most prevalent mental health disorders and has a significant societal economic burden. Antidepressants and cognitive behavioral therapy are two primary interventions for the standardized treatment of MDD. However, their weaknesses, such as a low response rate, a high risk of adverse events from medication, and the high cost of cognitive behavioral therapy, have resulted in a need for complementary and alternative medicine (CAM). Among the various therapeutic interventions in CAM, electroacupuncture and moxibustion have been widely used to treat various mental illnesses, including MDD. The aim of this study is to evaluate the feasibility of conducting a full-scale randomized controlled trial to investigate the efficacy and safety of electroacupuncture plus moxibustion therapy for MDD. METHODS/DESIGN: We will include patients between the ages of 19 to 65 years with MDD. A total of 30 participants will be recruited, and they will be randomly allocated into two groups at a 1:1 ratio. Patients in the treatment and control groups will, respectively, receive real and sham electroacupuncture/moxibustion treatments, for a total of 20 sessions over 8 weeks. The primary outcome will be the Hamilton Rating Scale for Depression, and the secondary outcomes will be Beck's Depression Inventory, the Insomnia Severity Index, the State-Trait Anxiety Inventory, the EuroQol 5-Dimension Index, the Measure Yourself Medical Outcome Profile version 2, and electroencephalography. Adverse events will be monitored at each visit to assess safety. All outcomes will be assessed and analyzed by researchers blinded to the treatment allocation. DISCUSSION: This is a two-armed, parallel-design, patient-assessor blinded, multicenter, randomized, sham-controlled pilot clinical trial. Data will be analyzed before and after treatment and during a 4-week follow-up. The results of the trial will provide a basis for further studies assessing the efficacy and safety of electroacupuncture plus moxibustion treatment for MDD. TRIAL REGISTRATION: Korean Clinical Trial Registry, CRIS-KCT0001810 . Registered on 5 February 2016 (retrospectively registered; date of enrollment of the first participant to the trial: 2 December 2015).
引用
- Kim M, Choi EJ, Kim SP, et al. Electroacupuncture plus moxibustion therapy for patients with major depressive disorder: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28086934. doi:10.1186/s13063-016-1741-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。